Company Website

Contact Information:

Andrea McCorkle
mccorkle.andrea@gene.com
6507456306

Melanie Hobson
hobson.melanie@gene.com
7022856586

Virtual Exhibit Hall Home

ENSPRYNG is the first and only treatment for AQP4-IgG(+) NMOSD that blocks IL-6 signaling. Watch the video to see how IL-6 plays a role in disease development and treatment.

Indication and Important Safety Information

ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children. ENSPRYNG may cause serious side effects including infections, increased liver enzymes, and low neutrophil counts. All required vaccinations should be completed before starting ENSPRYNG. Do not take ENSPRYNG if you are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG, have an active hepatitis B infection, or have active or untreated inactive (latent) TB. These are not all possible side effects of ENSPRYNG. See full Important Safety Information at https://bit.ly/ENSPRISI and see Prescribing Information in the Additional Information below.

To learn more about ENSPRYNG and its well-studied safety profile, with a median exposure of 5 years, please visit www.enspryng-hcp.com/safety/safety-profile

Additional Information:
Prescribing Information
Core Data Brochure